Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. Improved Outcomes With Complete Metastasectomy in Metastatic RCC Patients
  2. Cabozantinib Plus Atezolizumab for Non-Clear Cell Renal Cell Carcinoma
  3. Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell Carcinoma
  4. Treatment Selection for mRCC Based on Gene Expression
  5. Novel Therapies for mRCC
  6. Cabozantinib Plus Nivolumab for First-Line mRCC
  7. Biopsy Cell Cycle Proliferation Score Predicts Adverse Surgical Pathology in Localized Renal Cell Carcinoma
  8. Pushing the Limits of Metastasis-Directed Treatment in mRCC in the Era of Targeted Therapy
  9. Patients With mRCC of T4 Stage With N1 Stage or Who Are Older Than 76 Years Do Not Benefit From Cytoreductive Nephrectomy
  10. Avelumab Plus Axitinib vs Sunitinib in Advanced RCC: Biomarker Analysis

Elsewhere

Recently Updated